• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bioceres Crop Solutions Corp. (Amendment)

    11/18/22 1:30:50 PM ET
    $BIOX
    Agricultural Chemicals
    Industrials
    Get the next $BIOX alert in real time by email
    SC 13G/A 1 d9809805_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 8)*

     

     

    Bioceres Crop Solutions Corp.
    (Name of Issuer)

     

     

    Ordinary Shares, par value US$0.0001 per share
    (Title of Class of Securities)

     

     

    G1117K114
    (CUSIP Number)

     

     

    November 15, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    CUSIP No G1117K114    

      

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      DRACO Capital Investment Management Company Ltd  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [X]
        (b)  []
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      British Virgin Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      215,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      215,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      215,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.34%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    OO, IA

     

     

     

     

     
     


     

    CUSIP No G1117K114    

      

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [X]
        (b)  []
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      British Virgin Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      215,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      215,000  
           

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      215,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
                                                                                                          [_]  
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      0.34%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      CO  

     

     
     

     

    CUSIP No G1117K114    

      

    Item 1. (a). Name of Issuer:
         
        Bioceres Crop Solutions Corp.
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    Ocampo 210 bis Predio CCT,

    Rosario, Santa Fe, Argentina

         
         
    Item 2. (a). Name of Person Filing:
         
       

    DRACO Capital Investment Management Company Ltd

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO

         
      (b). Address of Principal Business Office, or if None, Residence:
         
       

    DRACO Capital Investment Management Company Ltd

    3076 Sir Francis Drake’s Highway

    PO Box 3463

    Road Town, Tortola

    British Virgin Islands

     

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO

    3076 Sir Francis Drake’s Highway

    PO Box 3463

    Road Town, Tortola

    British Virgin Islands

     

         
      (c) Citizenship:
         
       

    DRACO Capital Investment Management Company Ltd – British Virgin Islands

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – British Virgin Islands

     

         
      (d).   Title of Class of Securities:
         
        Ordinary Shares, par value US$0.0001 per share
         
      (e). CUSIP Number:
         
        G1117K114
         

     

     


    Item 3.
      If this Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

           
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

     

     
    Item 4. Ownership.
     
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a)   Amount beneficially owned:
         
       

    DRACO Capital Investment Management Company Ltd – 215,000

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – 215,000

     

         
      (b)   Percent of class:
         
       

    DRACO Capital Investment Management Company Ltd – 0.34%

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – 0.34%

     

         
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote    
         

     

    DRACO Capital Investment Management Company Ltd – 0

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – 0

     

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    DRACO Capital Investment Management Company Ltd – 215,000

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – 215,000

     

     

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    DRACO Capital Investment Management Company Ltd – 0

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    DRACO Capital Investment Management Company Ltd – 215,000

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO – 215,000

     

     
                 

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
       

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].
     
       
       

      

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
        N/A

     

     
     

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      N/A    

     

     


    Item 8.
    Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     

     

        See Exhibit A attached hereto.

     

    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     

     

        N/A

     

    Item 10. Certification.
     
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
         

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      DRACO Capital Investment Management Company S.A.
      By: /s/ German Firpo
      (Signature)
       
       
      German Firpo, President
      (Name/Title)

     

     

      November 18, 2022
      (Date)

     

       
      DRACO Capital Investment Management Company Ltd
      By: /s/ Ignacio Fravega
      (Signature)
       
       
      Ignacio Fravega, Director
      (Name/Title)

     

     

      November 18, 2022
      (Date)
       
       
     

    DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO

    By: /s/ Ignacio Fravega

      (Signature)
       
       
      Ignacio Fravega, Director
      (Name/Title)

     

     

      November 18, 2022
     

    (Date)

     

     

     

    *The Reporting Persons disclaim beneficial ownership in the shares reported herein except to the extent of their pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G amendment dated November 18, 2022 relating to the Ordinary Shares, par value US$0.0001 per share of Bioceres Crop Solutions Corp. shall be filed on behalf of the undersigned.

     

      DRACO Capital Investment Management Company S.A.
      By: /s/ German Firpo
      (Signature)
       
       
      German Firpo, President
      (Name/Title)

     

     

      November 18, 2022
      (Date)
       
       
      DRACO Capital Investment Management Company Ltd
      By: /s/ Ignacio Fravega
      (Signature)
       
       
      Ignacio Fravega, Director
     

    (Name/Title)

     

     

      November 18, 2022
      (Date)

     

     

    DRACO I EVENT OPPORTUNITY SEGREGATED
    PORTFOLIO
    By: /s/ Ignacio Fravega

      (Signature)
       
       
      Ignacio Fravega, Director
      (Name/Title)  

     

     

      November 18, 2022
      (Date)

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on

    behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    EXHIBIT A

    The members of the group are:

    1.DRACO Capital Investment Management Company Ltd
    2.DRACO I EVENT OPPORTUNITY SEGREGATED PORTFOLIO

    Get the next $BIOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOX

    DatePrice TargetRatingAnalyst
    7/19/2024$17.00Buy
    Canaccord Genuity
    7/2/2024$15.00Buy
    ROTH MKM
    4/6/2023$15.00Outperform
    Oppenheimer
    9/30/2022$22.50Buy
    Canaccord Genuity
    10/8/2021$21.00Buy
    ROTH Capital
    More analyst ratings

    $BIOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

      Total revenues in 3Q25 were $60.6 million 3Q25 net loss was $1.6 million and Adjusted EBITDA1 was $9.0 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues were $60

      5/21/25 7:01:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions to Host Fiscal Third Quarter 2025 Financial Results Conference Call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal third quarter ended March 31, 2025. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube, Chief Commercial Officer Milen Marinov and Head of Investor Relations Paula Savanti will host the conference ca

      5/9/25 4:30:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Announces EPA Registration of Rinotec Insecticide and Nematicide Platform, a Game-Changing Solution for Integrated Pest Management

      Bioceres Crop Solutions (NASDAQ:BIOX), a leading global provider of sustainable crop productivity solutions, and ProFarm Group, a subsidiary of BIOX, today announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA's assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regi

      3/11/25 7:30:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bioceres Crop Solutions Corp.

      SC 13G - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      10/23/24 2:32:38 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp.

      SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      9/20/24 9:09:41 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp. (Amendment)

      SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      3/25/24 8:58:35 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on Bioceres with a new price target

      Canaccord Genuity resumed coverage of Bioceres with a rating of Buy and set a new price target of $17.00

      7/19/24 8:32:10 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • ROTH MKM resumed coverage on Bioceres with a new price target

      ROTH MKM resumed coverage of Bioceres with a rating of Buy and set a new price target of $15.00

      7/2/24 8:01:46 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Oppenheimer initiated coverage on Bioceres with a new price target

      Oppenheimer initiated coverage of Bioceres with a rating of Outperform and set a new price target of $15.00

      4/6/23 7:19:53 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    SEC Filings

    See more
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      5/21/25 4:44:06 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      3/11/25 4:01:14 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      2/12/25 8:04:36 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Financials

    Live finance-specific insights

    See more
    • Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

      Total revenues in 3Q25 were $60.6 million 3Q25 net loss was $1.6 million and Adjusted EBITDA1 was $9.0 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues were $60

      5/21/25 7:01:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions to Host Fiscal Third Quarter 2025 Financial Results Conference Call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal third quarter ended March 31, 2025. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube, Chief Commercial Officer Milen Marinov and Head of Investor Relations Paula Savanti will host the conference ca

      5/9/25 4:30:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results

      Total revenues in 2Q25 were $106.7 million 2Q25 net income was $0.6 million and Adjusted EBITDA1 was $15.4 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal second quarter ended December 31, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Revenues in

      2/11/25 6:18:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials